Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Long-term benefits of ranibizumab in neovascular AMD patients

Nov. 9, 2004

No Comments

Inspire licenses novel glaucoma technology

Nov. 9, 2004

No Comments

Serotonin receptor agonists for treatment of ocular hypertension and glaucoma

Nov. 4, 2004

No Comments

Series B financing at Othera to accelerate pipeline development

Oct. 27, 2004

No Comments

Treatment under way in TheraSight trial

Oct. 25, 2004

No Comments

Visudyne VIO study recommended to continue

Oct. 18, 2004

No Comments

Anecortave acetate study results

Oct. 18, 2004

No Comments

Cand5 enters phase I study for AMD

Oct. 14, 2004

No Comments

Photrex chosen as new brand name for SnET2

Oct. 11, 2004

No Comments

Squalamine granted fast track status for wet AMD

Oct. 7, 2004

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Ocular
RSS

Long-term benefits of ranibizumab in neovascular AMD patients

Inspire licenses novel glaucoma technology

Serotonin receptor agonists for treatment of ocular hypertension and glaucoma

Series B financing at Othera to accelerate pipeline development

Treatment under way in TheraSight trial

Visudyne VIO study recommended to continue

Anecortave acetate study results

Cand5 enters phase I study for AMD

Photrex chosen as new brand name for SnET2

Squalamine granted fast track status for wet AMD

Today's news in brief

Today's news in brief

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

Proteomics study explores how protein changes influence disease

Abbvie and Simcere enter a $1B T-cell engager deal

Ocular RSS

Ocular
RSS